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1 We investigated the eect of the NO-donor S-nitroso-N-acetyl-DL-penicillamine (SNAP) on
cardiomyocytes isolated from control normotensive Wistar Kyoto (WKY) and spontaneously
hypertensive (SHR) rats.
2 Ventricular cardiomyocytes were isolated from SHR and WKY hearts and imaging analysis of
fura-2-loaded cells was performed in order to evaluate calcium transient in electrical field paced
(0.5 Hz) cells.
3 In WKY cardiomyocytes, 1 – 200 mM SNAP dose-dependently increased cyclic GMP content. In
basal conditions, cyclic GMP content of SHR cardiomyocytes was significantly higher than in
WKY, but SNAP failed to further increase cyclic GMP over the basal level.
4 In control conditions, the DF/F and decay time of the calcium transient were similar in both
strains. In WKY cardiomyocytes, SNAP (1 – 100 mM) reduced the decay time. In SHR
cardiomyocytes, SNAP was ineective. Dibutyryl cyclic GMP (1076 – 1078 M), a membrane
permeable cyclic GMP analogue, behaved similarly to SNAP.
5 In WKY and SHR cardiomyocytes, 1078 M isoprenaline similarly increased DF/F and decreased
the decay time. SNAP and dibutyryl cyclic GMP prevented the eect of isoprenaline in WKY,
whereas both molecules were ineective in SHR cardiomyocytes. In WKY, SNAP eects were
blocked by pretreating cells with the cGK inhibitor KT-5823.
6 Western blotting analysis of cGK type I showed that the enzyme was expressed in WKY isolated
cardiomyocytes, but absent in four out of five SHR preparations.
7 We concluded that the low expression of cGKI may determine the lack of NO/cyclic GMP-
dependent regulation on calcium transient in SHR cardiomyocytes. This alteration may contribute
to the development of heart hypertrophy in hypertensive status.
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Introduction
Nitric oxide (both endogenous produced and exogenous
applied as NO-donor molecules) can regulate the heart rate
and contractility (for recent review see Balligand, 1999;
Paulus & Shah, 1999). In particular nitric oxide can exert
either a positive or a negative inotropic eect according to
dose (Kojda et al., 1996; Mohan et al., 1996) and inhibits
the b-adrenergic-mediated positive inotropic eect (Balli-
gand et al., 1993). Several NO eects are mimicked by
guanosine 3’:5’-cyclic monophosphate (cyclic GMP) analo-
gues (Shah et al., 1994 ; Mohan et al., 1996), blocked by
cyclic GMP pathway interfering agents (Kojda et al., 1997)
and an increase in cyclic GMP after NO stimulation is
documented in heart preparations (Mery et al., 1993; Kaye
et al., 1996), thus suggesting that soluble guanylyl cyclase
activation is mainly involved in NO actions. Cardiomyo-
cytes express the constitutive type III nitric oxide synthase
(eNOS, NOS III – Balligand et al., 1995). In the rat, the
enzyme is activated by muscarinic cholinergic agonists
(Balligand et al., 1993; 1995) and by a high frequency rate
(Kaye et al., 1996). The exact mechanism(s) by which NO
regulates cardiomyocyte functions is still controversial.
Cyclic GMP can inhibit type 3 phosphodiesterase (PDE3)
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and activates type 2 phosphodiesterase (PDE2), thus
regulating the cyclic adenosine 3’:5’-cyclic monophosphate
(cyclic AMP) content in an opposite direction and therefore
influencing the b-adrenergic-mediated positive inotropic
eect (Hove-Madsen et al., 1996). Several phosphodiesterase
subtypes are involved in the regulation of L-type calcium
current in rat ventricular cardiomyocytes (Verde et al.,
1999) and can therefore strongly influence the b-adrenergic-
mediated positive inotropic eect. Moreover, cyclic GMP
can decrease L-type calcium current stimulated by cyclic
AMP through the activation of a cyclic GMP-dependent
protein kinase (cGK) in rat ventricular cardiomyocytes
(Mery et al., 1991). Other cyclic GMP-dependent mechan-
isms can not be excluded (Balligand, 1999).
On the other hand, NOSIII-deficient mice (NOS3-KO) do
not show cardiac abnormalities, and muscarinic agonists can
still regulate b-adrenergic-mediated inotropic eect and
inhibit L-type calcium current, indicating at least in this
genetically engineered experimental model a minor role of
NO in the anti-adrenergic muscarinic action (Vandecasteele et
al., 1999).
However, NO fails to antagonize the b-adrenoceptor
mediated positive inotropic eect in left ventricular strips
isolated from 12 – 16-week-old spontaneously hypertensive
rats (SHR), while in WKY left ventricular strips the increase
in contractile force induced by isoprenaline is prevented by S-
nitroso-N-acetyl-DL-pencillamine (SNAP) (Kotchi Kotchi et
al., 1998). Whereas in WKY ventricular strips 1075 M SNAP
shifts the isoprenaline dose-response curve to the right, it is
ineective in SHR.
This loss of NO regulatory eect in SHR ventricular strips
could be dependent on the decreased activity of cGK
measured in homogenized ventricular and atrial tissue as a
decrease in cyclic GMP-dependent phosphorylated proteins
(Kuo et al., 1976). A decreased concentration of cGK is also
described in stroke-prone SHR and renovascular hypertensive
rats (Goldblatt II) cardiac tissue extracts by Ecker et al.
(1989). Using a radioimmunoassay and enzyme-linked
immunosorbent assay methodology, the authors demonstrate
a half concentration of cGK in stroke-prone SHR total heart
extract. However, these authors demonstrate a similar high
expression of cGK in coronary smooth muscle cells of both
strains by immunohistochemical and therefore they conclude
that the low content of cGK is mainly due to a low index of
vascularization in stroke-prone SHR hearts since cGK
expression is very low in cardiomyocytes. This cGK decrease
is selectively present only in the heart, but not in aorta and
brain microvessels.
In microcoronary endothelial cells isolated from 12-week-
old SHR, we demonstrated that the intracellular calcium is
not regulated by endogenous and exogenous applied NO
(Failli et al., 2000). We reasoned that a similar calcium
deregulation may be responsible for the loss of NO-
mediated prevention of b-adrenergic eect in SHR
cardiomyocytes.
Therefore the aim of our study was to evaluate the eect of
exogenous applied NO and cyclic GMP on the calcium
transient in paced ventricular cardiomyocytes isolated from
SHR heart and to compare these data with those obtained in
WKY cardiomyocytes. Preliminary data of this research were
presented at the XIIIth International Congress of Pharma-
cology (Failli et al., 1998).
Methods
Isolation of ventricular cardiomyocytes and
microcoronary endothelial cells
This investigation conforms to the rules for the care and use
of laboratory animals of the European Community.
Cardiomyocytes were isolated from 12 – 15-week-old WKY
and age-matched SHR (Charles River, Italy) as described
(Failli et al., 1992). Briefly, hearts were mounted in
Langendor’s apparatus, washed for 5 min with nominally
calcium-free Krebs-Heinselet solution (K-H, mM composi-
tion): NaCl 110, NaHCO3 25, KCl 4.8, KH2PO4 1.2, MgCl2
1.2, D(+)glucose 11, 10 taurine, and then perfused for
20 min with KH containing 0.1% type I collagenase (Sigma
Chemical Co., St. Louis, Missouri, U.S.A.), 0.1% fraction V,
fatty acid free bovine serum albumin (BSA, Roche Molecular
Biochemicals, Milan, Italy). Ventricles, including the septum,
were cut in small pieces and fragments were dispersed in K-
H, 100 mM CaCl2 and 1% BSA. After centrifugation (256 g
for 3 min), the pellet containing heavy cells was resuspended
in 10 ml of K-H solution, 100 mM CaCl2 and cardiomyocytes
were purified using a discontinuous BSA gradient (4%).
Microcoronary endothelial cells (MCECs) were obtained
from the supernatant, purified as described and used at the
first culture passage (Failli et al., 2000). Solutions were gassed
with 95% O2: 5% CO2. All the perfusion steps were
performed at 378C, whereas heart disgregation and cardio-
myocyte purification were conducted at room temperature
(20 – 258C). Only suspensions containing more than 70% of
rod-shaped cardiomyocytes were used for further investiga-
tions. Contamination from other cell types were evaluated as
being less than 7%.
Cyclic GMP determination
Cardiomyocytes (56105 cells ml71) were preincubated
(10 min) with K-H containing 100 mM isobutylmethyl-
xanthine (IBMX, Sigma Chemical Co.); cells were then
incubated for 5 min at 378C in either control conditions or
with SNAP (final concentration 200, 100, 10 and 1 mM).
Reaction was stopped by cooling and centrifugation (5006 g
for 5 min); the supernatant was discharged and cyclic GMP
was twice extracted with ice-cold 65% ethanol. Hydroalco-
holic supernatant was dried under N2 stream (Lin et al.,
1995) and used for the determination of cyclic GMP using a
commercial [3H]-cyclic GMP RIA Kit (Amersham Interna-
tional).
Western blot analysis of type I cGK
Cardiomyocytes and confluent MCECs were lysed in RIPA
buer (mM composition): Tris-HCl 20, ph 7.4, NaCl 150,
EDTA 5, Na3VO4 1, phenyl methyl sulphonyl fluoride 1;
nonidet P-40 1%, aprotinin 0.05% [w/v]. Insoluble proteins
were discarded by high-speed centrifugation at 48C. Protein
concentration in the supernatant was measured in triplicate
(Bradford, 1976). Western blot analysis was carried out
essentially as described elsewhere (Marra et al., 1997).
Proteins (75 mg) were separated by 10% SDS–PAGE
according to Laemmli (1970) and electroblotted on a
polyvinyliden-difluoride membrane. The membranes were
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blocked overnight at 48C with 2% BSA in 0.1% PBS –
Tween, and then sequentially incubated at room temperature
with the primary rabbit polyclonal antibody for cGK typeI
(cGKI) and horseradish peroxidase-conjugated secondary
antibodies. Detection was carried out using chemilumines-
cence according to the manufacturer’s protocol (Amersham,
Arlington Heights, IL, U.S.A.).
Immunocytochemistry of cGKI in MCECs MCECs were
grown until confluence on tissue culture chamber slides (Lab-
tek, Nunc Inc., Naperville, Il, U.S.A.) and fixed in 10%
formaldehyde solution. The slides were incubated overnight
at RT with the primary polyclonal rabbit antibody for cGKI
(used at a 1 : 600 dilution in PBS containing 0.1% Triton-X
and 0.5% BSA). On the following day, they were washed and
incubated for 1 h at RT with the anti-rabbit secondary
antibody Cy3 (Sigma) diluted 1 : 500 in PBS – 0.5% BSA and
0.1% Triton-X. Analysis was performed by means of a
Nikon Labophot-2 epifluorescence microscope. Negative
control for the immunostaining was obtained by omission
of the primary antibody. No fluorescence was detected in
absence of the primary antibody.
Imaging analysis of fura-2 fluorescence and cytosolic
intracellular calcium
Isolated cardiomyocytes were resuspended at a density of
500,000 cells ml71 in 500 mM CaCl2 K-H solution and loaded
with 4 mM fura-2AM (Grynkiewicz et al., 1985) for 45 min at
room temperature. Cells were washed and resuspended in K-
H 1.5 mM CaCl2. Fura-2 loaded cardiomyocytes were
sedimented into a perfusion chamber supporting two
platinum wires (distance between electrodes: 10 mm) con-
nected with an electrostimulator (Harvard Apparatus, South
Natick, Massachusetts, U.S.A.) and placed on the stage of an
inverted fluorescence microscopy (Nikon Diaphot, Tokyo,
Japan) equipped with a 75 W UV–Xenon lamp. Cells were
paced by electrical field stimulation at 0.5 Hz, 100 mV peak
voltage. Imaging analysis of fura-2 specific fluorescence was
performed. Fluorescence images obtained at the single
excitation wavelength of 380 nm, emission 510 nm (Ishide
et al., 1990; Failli et al., 1997) were collected with an
intensified charge coupled device (CCD) video camera ISIS-
M extended camera (Photonic Science, U.K.) at video rate
(25 Hz), digitalized by an analogical to digital converter
(2566256 pixels68 bits) and dynamically analysed on-line
using an image analysis, Microsoft Windows based software
(Autolab1, RCS, Florence, Italy). Fluorescence of fura-2 was
converted in a grey scale recognizing 256 levels. Experiments
were performed at 328+18C. The excitation wavelength of
380 nm for fura-2 was chosen in order to evaluate fura-2
fluorescence in an optimal linear range during electrical field
stimulation. All cells found in an optical field (using 206
magnification objective) were analysed. The following para-
meters of the calcium transient induced by electrical-field
stimulation were evaluated: the ratio between the fluorescence
maximal variation induced by electrical-field stimulation and
the diastolic fluorescence (DF/F) and the decay time (see
later, mathematical method). Fura-2 loading of WKY and
SHR cardiomyocytes was homogeneous and the fluorescence
intensity of whole cells was similar in both strains. In control
experiments after recording the calcium transient in basal
condition for at least 3 min, SNAP, dibutyryl guanosine 3’:5’-
cyclic monophosphate (cyclic dibutyryl GMP), N-acetyl-DL-
penicillamine (AcPen) or the solvent were administered and
followed by 1078 M isoprenaline after 6 min. Electrical pacing
was followed for at least 6 min after isoprenaline. Cardio-
myocytes were incubated 10 min with KT-5823 before
performing experiments.
Intracellular calcium quantification performed with the
ratiometric method (Failli et al., 1992) showed that the
intracellular calcium concentration in unstimulated cardio-
myocytes was not significantly dierent in either strain
(126+7.1 nM, c=12, n=5 and 135+4.1 nM, c=11, n=4 in
WKY and SHR respectively).
Data were exported as ASCII file format and elaborated
for graphic presentation using MicroCal Origin1 (2.8
version).
Materials L-NMMA, isoprenaline, (d,l)propranolol, cyclic
dibutyryl GMP and AcPen were purchased from Sigma
Chemical Co. (Milan, Italy). SNAP was purchased from
Tocris Cookson Ltd. (Bristol, U.K.), KT-5823 an inhibitor of
cyclic GMP-dependent protein kinase (Kase et al., 1987) by
Calbiochem (Milan, Italy), and fura-2AM from Molecular
Probes (Eugene, Oregon, U.S.A.). All other reagents were of
analytical grade. The cGKI polyclonal antibody was a kind
gift of Prof Franz Hofmann.
Mathematical and statistical methods
For each experimental protocol, 2 – 4 cardiomyocytes isolated
from at least three dierent hearts were analysed. The
number of cells analysed is reported as c and the number
of dierent preparations used as n. Values are presented as
means+s.e.mean of analysed cells (c). In order to fit calcium
transient decay with a mono-exponential mathematical
function, data were subtracted from the reference value of
256 gray levels. The decay time of calcium transient was
calculated according to the followed equation:
Y  y0 A : eÿx :  1
According to the fitting function, the ‘tau’ (t) parameter
represented the time necessary for [Ca2+]i to reach 36.79% of
the maximal value. The constant ‘tau’ of the monoexponen-
tial fitting was therefore reported as the decay time value
(ms). At least six calcium transients for each dierent
treatment were analysed and averaged.
Statistical comparisons between data groups were per-
formed using Student’s t-test (paired or independent as
indicated); dose-response curves were also analysed by one-
way ANOVA. A P value of 50.05 was considered
significant.
Results
Effect of SNAP on cyclic GMP content in
cardiomyocytes
As shown in Figure 1, SNAP (1 – 200 mM) dose-dependently
increased cyclic GMP content in WKY cardiomyocytes
(F=3.128, P50.05, one-way ANOVA, n=5). In SHR
cardiomyocytes, cyclic GMP content in basal conditions
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was significantly higher than in WKY, but SNAP failed to
further increase cyclic GMP over the basal level at all doses
tested. Indeed, at all SNAP doses tested no dierence from
basal level was observed (Figure 1).
Electrical pacing in ventricular cardiomyocytes
In control conditions electrical field stimulation in both
WKY and SHR cardiomyocytes induced a typical calcium
transient as observed by the change in the fura-2 fluorescence
(Figure 2). The DF/F and decay time were similar in both
strains (Figure 3). Isoprenaline (1078 M) increased the DF/F
by about +4.5% in WKY (c=64, n=21) and by +4.0% in
SHR (c=58, n=18) and decreased the decay time (717.6%,
736.2+2.84 ms in WKY and 715.5%, 730.3+1.98 ms in
SHR respectively), its eect being comparable in both WKY
and SHR cardiomyocytes (Figure 3). This eect was observed
shortly (60 – 120 s) after addition of isoprenaline, and still
present after 10 min in the continuous presence of the drug.
In both strains, 1076 M (d,l)propranolol prevented isoprena-
line eects.
Effect of SNAP and dibutyryl cyclic GMP on fura-2
fluorescence
Eect of SNAP and dibutyryl cyclic GMP in basal
conditions Then, we analysed the eect of SNAP (1 –
200 mM) on fura-2 fluorescence in unstimulated and in
electrical-field stimulated cells. No significant changes in
fura-2 fluorescence were observed when SNAP was adminis-
tered to unpaced cardiomyocytes in both strains. However, in
paced WKY cardiomyocytes, 200 mM SNAP induced a
modest (not significant) increase in decay time, whereas in
the range 100 – 1 mM SNAP significantly reduced it (Table 1).
These eects were measured after 300 – 480 s of SNAP. The
amplitude of calcium transient was not modified. In SHR
cardiomyocytes, SNAP slightly decreased the decay time at
the higher dose tested, but was ineective in the 100 – 1 mM
range. Dibutyryl cyclic GMP, a membrane permeable cyclic
GMP analogue, behaved similarly to SNAP. Indeed,
dubutyryl cyclic GMP in the dose range 1076 – 1078 M
reduced the decay time in WKY, while it was practically
ineective in SHR (Table 2).
Eect of isoprenaline on SNAP- and dibutyryl cyclic GMP-
treated cells Thereafter we tested the eect of 1078 M
isoprenaline in SNAP-treated myocytes. In WKY cardio-
myocytes, SNAP (administered 6 min before 1078 M iso-
prenaline) prevented the eect of isoprenaline. The increase in
DF/F was totally blocked by SNAP, while the decrease in
decay time was dose-dependently reduced, 1075 M SNAP
being the more eective dose (Figure 4, F=8.73, P50.01,
one-way ANOVA). Administration of 200 mM AcPen in
control conditions did not influence either the DF/F or the





Figure 1 Cyclic GMP content of WKY and SHR ventricular
cardiomyocytes after preincubation with buer (control) or in the
presence of 1 – 200 mM S-nitroso-N-acetylpenicillamine (SNAP).
Values are the mean(+s.e.mean) of five independent experiments.
*P50.05 one-way ANOVA; }P50.001 vs control, WKY.
Figure 2 Typical time-course of fura-2 fluorescence in an electrical-
field stimulated WKY cardiomyocyte paced at 0.5 Hz. Fura-2
fluorescence was obtained at 380 nm excitation wavelength, emission
510 nm. For graphical presentation values were subtracted from a
reference value of 256 gray levels. Isoprenaline (1078 M) was
administered as indicated and maintained till the end of the
experiment. The upper panel shows a magnification of calcium
transients in control conditions (before axis break) and after
isoprenaline.
Figure 3 Eect of 1078 M isoprenaline on DF/F and decay time in
WKY (c=64, n=24) and SHR (c=55, n=16) ventricular cardio-
myocytes. ***P50.001 vs control, Student’s t-test, paired data.
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in DF/F and the decrease in decay time induced by 1078 M
isoprenaline. Indeed, the DF/F increase induced by isoprena-
line in AcPen-treated cardiomyocytes was 4.8+0.82% (c=18,
n=6) of basal value, a value similar to that obtained in
control conditions. Also the decrease in the decay time was
38+4.48 ms (c=18, n=6) in 200 mM N-AcPen treated cells;
this value was not significantly dierent from that obtained in
control conditions. Moreover, in WKY cardiomyocytes
dibutyryl cyclic GMP in the 1076 – 1078 M dose range
blocked the increase in DF/F induced by isoprenaline and
dose-dependently counteracted the decrease in decay time
(F=4.78, P50.01 one-way ANOVA, Figure 5). Neither the
DF/F, nor the decay time were significantly modified by
either SNAP or dibutyryl cyclic GMP in SHR cardiomyo-
cytes (Figures 4 and 5).
Eect of KT-5823 In WKY cardiomyocytes, we tested the
influence of the cyclic GMP-dependent protein kinase
inhibitor KT-5823 on SNAP eects. The preincubation with
1 mM KT-5823 did not modify the DF/F and decay time as
compared to controls. The eect of 1078 M isoprenaline was
fully maintained; the increase in DF/F was 4.3+0.81%, while
decrease in the decay was 732.5+4.58 ms (c=8, n=3).
These values were not significantly dierent to those obtained
in control cells. However, after KT-5823 preincubation,
100 mM SNAP was ineective in reducing the decay time
and no longer prevented isoprenaline eects. After 1078 M
isoprenaline the increase in DF/F was +3.9+0.63% and the
decrease in decay time was 728.7+3.52 ms (c=7, n=3), an
eect similar to that induced by isoprenaline in cells
pretreated only with KT-5823.
cGKI expression in isolated cardiomyocytes and
microcoronary endothelial cells
Western blotting analysis of GK I showed that the enzyme
highly expressed in WKY isolated cardiomyocytes, but was
totally absent in four out of five SHR preparations, while in
one preparation it was expressed (Figure 6).
On the other hand, in isolated microcoronary endothelial
cells obtained from the same animal as cardiomyocytes,
cGKI was similarly expressed as determined by Western
analysis and immunocytochemistry (not shown).
Table 1 Eect of SNAP (200-1 mM) on the decay time of
isolated cardiomyocytes from WKY and SHR
WKY SHR






**P50.01 vs control, Student’s t-test paired data. Data are
reported as dierences from control values (before the
administration of drugs) and represent the mean
(+s.e.mean) of at least 11 cells obtained in four separate
experiments.
Table 2 Eect of dibutyryl cyclic GMP (107671078 M) on
the decay time of isolated cardiomyocytes from WKY and
SHR
WKY SHR
D decay time (ms)




*P50.05 vs control, Student’s t-test paired data. Data are
reported as dierences from control values (before the
administration of drugs) and represent the mean
(+s.e.mean) of at least 10 cells obtained in four separate
experiments.
Figure 4 Eect of 1 – 200 mM S-nitroso-N-acetylpenicillamine
(SNAP) on isoprenaline-induced decrease in decay time in WKY
and SHR ventricular cardiomyocytes. Each point is the mean
(+s.e.mean) of at least 15 cells obtained in at least five separate
experiments. Values are presented as D decay time (decay time SNAP
minus decay time 1078 M isoprenaline administered 6 min after
SNAP). For more details, see text. **P50.01, one-way ANOVA.
Figure 5 Eect of 1076 – 1078 M dibutyryl guanosine 3’:5’ cyclic
monophosphate (dibutyryl cyclic GMP) on isoprenaline-induced
decrease in decay time in WKY and SHR ventricular cardiomyo-
cytes. Each point is the mean (+s.e.mean) of at least 12 cells
obtained in at least four separate experiments. Values are presented
as D decay time (decay time dibutyryl cyclic GMP minus decay time
1078 M isoprenaline administered 6 min after dibutyryl cyclic GMP).
For more details, see text. *P50.05, one-way ANOVA.
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Discussion
Our data show that in WKY cardiomyocytes, the NO-donor
SNAP dose-dependently increases cyclic GMP content, the
highest eective dose being 100 mM. Therefore, the soluble
guanylyl cyclase (sGC) is present and active in WKY
cardiomyocytes. A dierent behaviour is present in SHR
cardiomyocytes. In control conditions cyclic GMP content is
higher in SHR cardiomyocytes than in WKY. However,
SNAP is unable to further increase cyclic GMP content in
SHR cardiomyocytes, suggesting a low or absent responsive-
ness of the enzyme. We have also described a reduced SNAP
responsiveness of sGC in MCECs isolated from SHR (Failli
et al., 2000), indicating that this alteration is common in
dierent cell types of SHR hearts. According to the result
obtained by Ruetten et al. (1999) the protein expression of
sGC (a and b subunits) is slightly increased in young SHR
hearts, whereas it is decreased in SHR aortic rings. This slight
increase in sGC protein expression might justify the high
basal cyclic GMP content in SHR cardiomyocytes, although
we can hypothesise alternative explanation of our data.
SNAP administration to electrical stimulated WKY
cardiomyocytes can induce in the dose interval of 1 –
100 mM a decrease in decay time, whereas at a higher dose
of 200 mM the decay time is slightly increased. Since the eect
of 100 mM SNAP is absent after blocking cGKI with KT5823
and the cyclic GMP analogue dibutyryl cyclic GMP in the
range 1076 – 1078 M reduces the decay time, the reduction in
decay time induced by SNAP is probably mediated by cyclic
GMP throughout the activation in cGKI. 200 and 100 mM
SNAP are equally eective in increasing cyclic GMP content
and therefore other pathways may influence the slight
increase in decay time observed with 200 mM SNAP.
In the range 1 – 200 mM SNAP linearly prevents the
decrease in decay time and the increase in DF/F induced by
isoprenaline. AcPen, the NO-lacking molecular skeleton of
SNAP, is ineective. Moreover, 100 mM SNAP no longer
counteracts the isoprenaline eect in the presence of a cGKI
block. Therefore, it is likely that SNAP activity is mediated
by a NO pathway that, increasing the cyclic GMP content,
activates the cGKI. The membrane permeable cyclic GMP
dibutyryl cyclic GMP (a membrane permeable cyclic GMP
analogous) behaves as SNAP in preventing the isoprenaline
eect, further supporting an involvement of cyclic GMP/
cGKI pathway in SNAP eectiveness. These results are in
line with earlier observations on NO antagonism of the b-
adrenergic inotropism (Balligand et al., 1993; also reviewed in
Balligand, 1999). Our data support a main role of cGKI in
SNAP eects, since SNAP is ineective in the presence of a
cGKI block, thus suggesting that cyclic GMP direct influence
on b-adrenergic inotropism is negligible in our condition.
On the other hand, in SHR cardiomyocytes SNAP is
unable to modulate calcium transient or to increase cyclic
GMP. A similar lack of NO eectiveness is observed also
with dibutyryl cyclic GMP. SNAP does not counteract the
decrease in decay time and the increase in DF/F induced by
isoprenaline. These results may explain the lack of b-
adrenergic inotropism modulation in SHR heart preparation
reported by Kotchi Kotchi et al. (1998). Since in WKY the
SNAP eect is mainly mediated by cGKI activation, we
analysed the expression of cGKI in cardiomyocytes of both
strains and found low or absent expression of cGKI in SHR
cardiomyocytes. This alteration is specific for SHR cardio-
myocytes as compared to MCECs, since in SHR MCECs, the
cGKI expression is similar to that observed in WKY. It
should be noted that the cGK activity is lower in SHR
ventricular and atrial homogenates than in WKY (Kuo et al.,
1976). Our data are only partially in agreement with those
reported by Ecker et al. (1989). On the other hand, we
detected the cGKI expression in cardiomyocytes by Western
blot while Ecker et al. (1989) analysed it immunohistochemi-
cally. However, we can not exclude alterations of other
cGKI-independent NO targets that can influence the
ineectiveness of NO/cyclic GMP pathway in SHR cardio-
myocytes. Although in NOS3-KO mice, b-adrenergic-
mediated positive inotropic eects are still antagonized by
muscarinic agents (Vandecasteele et al., 1999), these data do
not rule out a big NO influence in cardiomyocytes isolated
from naı¨ve animals, since alternative pathways may develop
in KO mice.
cGKI-deficient mice are hypertensive and show an
impaired NO/cyclic GMP mediated relaxation of smooth
muscles (Pfeifer et al., 1998). Moreover, the cGK gene
expression is down regulated in cultured rat VSMCs after
exposure to hypertrophic/hyperproliferative agents such as
platelet-derived growth factor, angiotensin II, transforming
growth factor-b, or tumour necrosis factor-a (Tamura et al.,
1996), indicating that this enzyme may play a role under
hypertrophic/hyperproliferative conditions. The low sCG
responsiveness to NO and the low expression of cGKI may
determine the lack of NO/cyclic GMP-dependent regulation
on calcium transient in SHR cardiomyocytes and can
therefore influence the cardiac hypertrophic status of SHR.
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Figure 6 Western blot analysis of cGKI in WKY and SHR
ventricular cardiomyocytes. The arrow indicates the cGKI band.
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